Latest market price
161.52
+0.73+0.45%
OverviewShort InterestFilings
NVSQT62Novartis AG·NYSE
161.52+0.45%
TA
Loading chart...
Signal & projected range
Analyst consensus risingHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AZN-0.04%$186.58MRK-0.78%$148.36AMGN-0.12%$465.45GILD-0.21%$170.33ABBV-2.02%$288.94NVO+1.13%$40.45PFE+0.49%$30.67JNJ-0.97%$270.56
Snapshot
Index—P/E30.82EPS (ttm)5.24Insider Own—Shs Outstand1.89BPerf Week5.01%
Market Cap305.05BForward P/E16.39EPS next Y9.86Insider Trans—Shs Float1.83BPerf Month14.55%
Enterprise Value344.11BPEG3.14EPS next Q2.24Short Float0.31%Perf Quarter5.38%
Income10.03BP/S5.42EPS this Y-0.70%Short Ratio2.85Perf Half Y11.69%
Sales56.31BP/B8.12EPS next Y11.18%ROA8.43%Short Interest5.59MPerf YTD17.15%
Book/sh19.89P/C33.99EPS next 5Y9.81%ROE24.24%52W High170.46 -5.24%Perf Year31.73%
Cash/sh4.75P/FCF20.56EPS past 3/5Y31.39% 15.36%ROIC13.96%52W Low122.57 31.78%Perf 3Y71.28%
Dividend Est.4.74 (2.93%)EV/EBITDA15.80Sales past 3/5Y8.04% 1.90%Gross Margin74.30%Volatility1.76% 1.56%Perf 5Y104.77%
Dividend TTM4.74 (2.93%)EV/Sales6.11EPS Y/Y TTM-28.32%Oper. Margin30.47%ATR (14)3.16Perf 10Y155.57%
Dividend Ex-DateMar 11, 2026Quick Ratio0.70Sales Y/Y TTM-0.12%Profit Margin18.06%RSI (14)69.61Recom2.84
Dividend Gr. 3/5Y6.30% 5.28%Current Ratio0.88EPS Q/Q9.33%SMA206.95%Beta0.40Target Price149.50
Payout89.56%Debt/Eq1.28Sales Q/Q4.67%SMA508.80%Rel Volume0.75Prev Close160.79
Employees75,267LT Debt/Eq1.02EarningsFeb 03SMA2006.33%Avg Volume2.05MPrice161.52
IPO DateNov 07, 1996Option/ShortYes / YesEPS/Sales Surpr.8.32% -0.07%Net Debt/EBITDA1.79Volume1,546,906Change0.45%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-30-26DowngradeDeutsche BankHold → Sell
Oct-28-26ReiteratedMorgan StanleyOverweight$156 → $163
Oct-06-26ReiteratedMorgan StanleyOverweight$170 → $156
Sep-10-26UpgradeHSBCReduce → Hold$112 → $136
Mar-26-26ReiteratedMorgan StanleyOverweight$143 → $170
Jan-06-26UpgradeBarclaysUnderweight → Equal Weight
Dec-10-25ReiteratedHSBCHold$106 → $112
Dec-08-25UpgradeJP MorganNeutral → Overweight
Dec-03-25ReiteratedMorgan StanleyEqual Weight$136 → $143
Oct-29-25ReiteratedCFRA$108 → $126
Latest News· Times ET
Nov-02-26
Nov-02-2604:14PM
BioArctic collaborator Novartis terminates agreementprnewswire.com
11:52AM
6 dividend stocks for investors who want to cut their exposure to the S&P 500marketwatch.com
08:02AM
Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol targetreuters.com
Nov-01-26
Nov-01-2601:00AM
Companies promised AI gains— here's how the payoff showed up in earningscnbc.com
Oct-31-26
Oct-31-2604:10AM
Novartis: Q3 2026 Earnings Confirm 'Hold' Recommendation Based On Balanced Approachseekingalpha.com
Oct-30-26
Oct-30-2601:01PM
All You Need to Know About Novartis (NVS) Rating Upgrade to Buyzacks.com
10:51AM
Why Novartis (NVS) is a Top Momentum Stock for the Long-Termzacks.com
02:00AM
A pharma giant is moving past one patent cliff — but another is already loomingcnbc.com
Oct-29-26
Oct-29-2607:38AM
Novartis AG (NVS) Q3 2026 Earnings Call Transcriptseekingalpha.com
Oct-28-26
Oct-28-2609:56AM
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radarzacks.com
07:00AM
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)Yahoo
Oct-27-26
Oct-27-2606:05PM
What Novartis (NVS) Said on Its Q3 Earnings Callmarketbeat.com
01:23PM
4 Arthritis Drug Stocks Investors Should Monitor for Growth Potentialzacks.com
12:51PM
NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Misszacks.com
11:38AM
Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9 Billion Avidity Hitbenzinga.com
Company

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue56,30654,81151,72246,660—————
Cost of Goods Sold Incl. D&A14,29013,69012,82712,472—————
Gross Profit42,01641,12238,89534,188—————
Selling, General and Administrative Excl. Other12,90113,30612,56612,517—————
Research and Development13,48610,74210,02211,371—————
Other Operating Expense1,29601,763531—————
Operating Income14,33417,07414,5449,769—————
Interest Expense1,5771,1871,036876—————
Unusual Expense
—————————
Non-Operating Income (Expense)-111549132230—————
Net Income Before Taxes12,64616,43613,6409,123—————
Income Taxes2,6312,3971,701551—————
Consolidated Net Income10,03314,05611,94114,850—————
Net Income From Continuing Operations10,01514,03911,9398,572—————
Net Income10,03314,05611,94114,850—————
EPS (Recurring)5.257.255.927.15—————
EPS (Basic, Before Extraordinaries)5.257.255.927.15—————
EPS (Diluted)5.247.195.877.10—————
EBITDA21,78422,98720,71518,255—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio30.8219.1816.5814.22—————
Price To Sales Ratio5.444.883.804.49—————
Gross Margin74.6275.0375.2073.27—————
Operating Margin25.4631.1528.1220.94—————
Net Margin17.8225.6423.0931.83—————
Shares Outstanding1,8961,9392,0182,077—————
Market Capitalization306,242267,330196,372209,715—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.